R oche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among individuals over 65. (CREDIT: CC BY-SA 4.0)© The Brighter Side of News Schematic of the overall experiments.

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

Geographic atrophy is an advanced form of dry age-related macular degeneration that causes vision loss in older adults. Until recently, there were no treatments available to target the root cause.

Presented October 26, 2018. Follow Medscape on Twitter @Medscape and Laird Harrison @LairdH ... Cite this: Fewer Injections With New Wet Macular Degeneration Therapies - Medscape - Oct 28, 2018.

Around 10 to 15 percent of people with dry AMD develop wet macular degeneration, according to the Macular Society. Wet AMD is more serious because new, abnormal blood vessels grow under the retina.

In July 2025, Novartis Pharmaceuticals organized a study is to assess the effect of Iptacopan to prevent conversion of early ...